Povidone-Iodine (PVI) has a profound effect on in vitro osteoblast proliferation and metabolic function and inhibits their ability to mineralise and form bone by Newton Ede, Matthew P. et al.
 
 
Povidone-Iodine (PVI) has a profound effect on in
vitro osteoblast proliferation and metabolic function
and inhibits their ability to mineralise and form bone
Newton Ede, Matthew P.; Philp, Ashleigh M.; Richardson, Stephen M.; Saeed, Mohammed;
Jones, Simon
DOI:
10.1097/BRS.0000000000001332
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Newton Ede, MP, Philp, AM, Richardson, SM, Saeed, M & Jones, S 2016, 'Povidone-Iodine (PVI) has a
profound effect on in vitro osteoblast proliferation and metabolic function and inhibits their ability to mineralise
and form bone', Spine, vol. 41, no. 9, pp. 729-734. https://doi.org/10.1097/BRS.0000000000001332
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This document constitutes the accepted version of the article detailed above. The final version of record is published as: Newton, Ede MP, et
al. "Povidone-Iodine (PVI) has a Profound Effect on in vitro Osteoblast Proliferation and Metabolic Function and Inhibits Their Ability to
Mineralise and form Bone." Spine (2015) and is available at: http://dx.doi.org/10.1097/BRS.0000000000001332
Checked Feb 2016
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
SPINE An International Journal for the study of the spine Publish Ahead of Print 
DOI : 10.1097/BRS.0000000000001332 
Povidone-Iodine (PVI) has a profound effect on in vitro osteoblast proliferation and 
metabolic function and inhibits their ability to mineralise and form bone 
Matthew P. Newton Ede1*M.B.B.S., Ashleigh M. Philp, MSc2*, Andrew Philp2PhD, Stephen 
M. Richardson3PhD, Saeed Mohammad4MD, Simon W. Jones2PhD 
*Denotes joint first authorship. 
 
1 The Royal Orthopaedic Hospital NHS Foundation Trust, Bristol Road South, Northfield, 
Birmingham, B31 2AP 
2 MRC-ARUK Centre for Musculoskeletal Ageing Research, Medical School, Queen 
Elizabeth Hospital, University of Birmingham, B15 2WB. 
3 Centre for Tissue Injury and Repair, Institute of Inflammation and Repair, Faculty of 
Medical and Human Sciences, The University of Manchester, Stopford Building, Oxford Rd, 
Manchester, M13 9PT 
4 Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD 
 
 
* Corresponding author  
Please address all correspondence to  
 
Simon W. Jones 
MRC-ARUK Centre for Musculoskeletal Ageing Research,  
Medical School, Queen Elizabeth Hospital, 
University of Birmingham,  
B15 2WB. 
Email: S.W.jones@bham.ac.uk 
+44 121 371 3224 
 
 
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
The device(s)/drug(s) that is/are the subject of this manuscript is/are not FDA-approved for 
this indication and is/are not commercially available in the United States. 
The British Scoliosis Research Foundation (BSRF) reference R114624 funds were received 
in support of this work.   
No relevant financial activities outside the submitted work. 
 
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Structured Abstract 
 
Study Design. A study examining the clinical protocol of scoliosis wound irrigation, 
demonstrating Povidone-Iodine’s (PVI) effect on human osteoblast cells.   Primary and 
immortal cell line osteoblasts were treated with 0.35% PVI for 3 minutes, and analyzed for 
proliferation rate, oxidative capacity and mineralisation.  
Objective.  To model spinal wound irrigation with dilute PVI in vitro, in order to investigate 
the effect of PVI on osteoblast proliferation, metabolism and bone mineralisation. 
Summary of Background Data.  Previously PVI irrigation has been proposed as a safe and 
effective practice to avoid bacterial growth following spinal surgery. However, recent 
evidence in multiple cell types suggests that PVI has a deleterious effect on cellular viability 
and cellular function.   
Methods.  Primary and immortal human osteoblast cells were exposed to either PBS control 
or with 0.35% PVI for 3 min.   Cellular proliferation was measured over the duration of 7 
days by MTS assay.  Oxygen consumption rate (OCR), extracellular acidification rate 
(ECAR) and proton production rate (PPR) were analysed using a Seahorse XFe24 
Bioanalyzer. Protein expression of the electron transport chain subunits CII-SDHB, CIII-
UQRCR2 and CV-ATP5A were measured via Western blotting.  Mineralised bone nodules 
were stained with alizarin red. 
 
Results. Expressed as a percentage of normal osteoblast proliferation, osteoblasts exposed to 
0.35% PVI exhibited a significant 24% decrease in proliferation after 24 h.  This was a 
sustained response, resulting in a 72% decline in cellular proliferation at 1 week.  There was a 
significant reduction in OCR, ECAR, and PPR (p<0.05), in osteoblasts that had been exposed 
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to 0.35% PVI for 3 min, coupled with a marked reduction in the protein expression of CII-
SDHB. Osteoblasts exposed to 0.35% PVI exhibited reduced bone nodule mineralisation 
compared to control PBS exposed osteoblasts (p<0.01). 
 
Conclusion.   PVI has a rapid and detrimental effect on human osteoblast cellular 
proliferation, metabolic function, and bone nodule mineralisation. 
 
Key Words:  Povidone-Iodine, PVI, Osteoblasts, wound irrigation, Spinal Surgery, Bone 
Mineralization, Cellular Metabolism, Cell Viability, Cell Proliferation 
 
Level of Evidence:  N/A 
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Introduction 
Surgical wound infection is a serious complication following spinal surgery. Infection rates in 
spinal surgery vary hugely and are dependent on a plethora of factors including patient co-
morbidities and type of surgery being performed. In particular deformity correction 
procedures, with long wounds, long operating times and medical co-morbidities; infection 
rates can be as high as 19%. Surgical site infections can progress to deep infection, incur 
multiple operations with increased healthcare costs and impaired patient outcomes (1-6). 
 
To reduce the risk of wound infections, many spinal surgeons are using intra-operative 
antimicrobial wound irrigates (7). One such irrigate which has been advocated and utilised is 
dilute Povidone-Iodine (PVI) (8). However, there is a paucity of evidence supporting this off-
label practice. Two clinical papers have previously described this as a safe and effective 
practice (8, 9) but there is evidence that PVI has a deleterious effect on cellular viability and 
cellular function. Studies across multiple cells types and tissues, including fibroblasts, 
keratinocytes, chondrocyte, immune cells and synovial tissue have now demonstrated that 
PVI has cytotoxic effects (10-13). 
 
The PVI wound irrigation technique, as described by Chang et al. (9), involves complete 
immersion of the wound for 3 minutes with a preparation of 0.35% of PVI (diluted from 
commercially available 10% PVI “Videne”), followed by copious irrigation with normal 
saline, prior to decortication and wound closure. 
 
Two laboratory studies (one human, one animal) describe the effects of PVI on osteoblasts. 
Whilst results were heterogeneous, all described a toxic effect of PVI on the osteoblast (14, 
15). 
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From a spinal surgery perspective, there are no studies which have examined whether PVI at 
clinically advocated concentrations has deleterious effects on human osteoblast viability and 
function. Addressing this is imperative since osteoblast proliferative and metabolic activity, 
together with their ability to form bone and mineralise, is essential for the establishment of 
solid fusion post-surgery.  
 
The aim of this study was to model the clinical protocol in vitro, in order to investigate the 
effect of dilute PVI washout on osteoblast proliferation, metabolic function and osteoblast 
bone nodule formation and mineralisation. 
 
METHODS 
3.1 Cell culture 
Primary human osteoblast cells were cultured in differentiation media (10% fetal calf serum 
(FCS), penicillin (100 units/ml), streptomycin (100µg/ml), L-glutamine (2mM), non-essential 
amino acids (1%, Invitrogen) and Amphotericin B (2.5 µg/ml), β-glycerophosphate (2mM), 
Ascorbic acid (50µg/ml) and Dexamethasome (10nM)) entirely. The human osteoblast cell 
line hFOB 1.19 (ATCC® CRL-11372™) (ATCC, England, UK) was cultured in growth 
media (1:1 mixture of Ham's F12 Medium Dulbecco's Modified Eagle's Medium, with 2.5 
mM L-glutamine (without phenol red), 10% fetal bovine serum (FBS), and 0.3mg/ml G418 
prior to differentiation media. 
 
3.2 Preparation of primary human osteoblasts 
Ethical approval was granted by the United Kingdom (UK) National Research Ethics Service 
(National Health Authority, reference NRES 14-ES-1044), and institutionally approved and 
sponsored by the University of Birmingham as required under the UK Research Governance 
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Framework. Study participants were provided in advance with a participant information 
sheet, and a participant consent form.  Following patient’s written consent, the femoral head 
was collected from a female patient (aged 62 years) undergoing total joint replacement 
surgery for hip osteoarthritis.  The articular cartilage was removed from the femoral head and 
the subchondral bone cut into small chips. The bone chips were then washed thoroughly in 
serum-free primary osteoblast media to remove any excess blood, connective or adipose 
tissue and then incubated in differentiation media in a culture flask at 37°C (5% CO2). 
Differentiation media was replaced with fresh media 2x per week, and the bone chips 
removed upon the appearance of osteoblast cells.  
 
3.3  Osteoblast proliferation assay 
Primary human osteoblasts and the human osteoblast cell line (hFOB 1.19) were plated at 
6x103 cells per well in a 96 well plate. At confluency, the cells were incubated with either 
PBS control or with 0.35% PVI (diluted in PBS) for 3 minutes at room temperature. The 
wells were then aspirated, washed 5x with PBS and then placed back into osteoblast growth 
media. After 24, 48, 120, 144 and 168 h at 33°C, an MTS (Cell Titer Aqueous One Solution 
Cell Proliferation Assay, Promega) assay was performed as per manufacturer’s instructions as 
a measure of osteoblast proliferation.  
 
3.4  Osteoblast metabolic function 
Human osteoblast cells (hFOB 1.19) were plated at 6x103 cells per well in an XFe 24 Cell 
Culture Microplate (Seahorse Bioscience, USA). At confluency, the cells were stimulated 
with 0.35% PVI diluted in PBS or with PBS control for 3min, thoroughly washed as 
described previously and placed back into growth media. After 24 h at 33°C, XF Assay 
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medium (XF base medium with 2mM GlutaMAX™) was then added to the plate and 
incubated at 33°C for 1 h.  
 
Using a XFe Extracellular Flux Analyzer (Seahorse Bioscience, USA) the oxygen 
consumption rate (OCR), extracellular acidification rate (ECAR) and proton production rate 
(PPR) of each well were measured simultaneously, in order to comprehensively profile the 
metabolic function of the osteoblasts. 
 
3.5  Expression analysis of osteoblast mitochondrial oxidative phosphorylation 
components 
Human osteoblast cells (hFOB 1.19) cells were seeded at 6x104 cells per well in a 24-well 
plate. Cells were stimulated with 0.35% dilute PVI or PBS control for 3min, and then washed 
in PBS as previously described before being cultured in growth media for 24 h (37°C, 5% 
CO2). Following 24 h, cells were washed in PBS and lysed in 1xLaemmli Sample Buffer 
(2%SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.002% Bromophenol Blue, 0.0625M Tris 
HCL).  Equal amounts of total protein lysates were then applied to 12% SDS PAGE 
electrophoresis and blotted onto polyvinylidene difluoride (PVDF) membrane at 150V for 1 
h. Blots were immunoprobed with an optimised antibody cocktail which contains antibodies 
to detect key components of mitochondrial oxidative phosphorylation, namely CII-SDHB 
30kDa (ab14714), CIII-UQCRC2 (ab14745) and CV-ATP5A (ab14748). Blots were 
developed using ECLTM Prime Western Blotting Detection Reagent Kit (GE Healthcare, UK) 
on the ChemiDocTM Imaging MP System (BIO-RAD, USA). 
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3.7 Osteoblast bone nodule formation and mineralization assay 
Human osteoblast cells (hFOB 1.19) were seeded at 6x104 cells per well in a 24 well plate 
and treated with or without 0.35% PVI for 3 min as described previously, before being 
cultured in differentiation media. After 14 days, cells were stained with alizarin red solution 
in order to quantify the degree of mineralisation following the formation of bone nodules. 
Briefly, cells were incubated in alizarin red staining solution (0.5% Alizarin Red (Sigma-
Aldrich, UK) in 1% ammonia solution at pH 4.5) for 10min at room temperature and washed 
with PBS to remove excess stain. Cells were then incubated in 10% cetyl pyridinium chloride 
(Sigma-Aldrich, UK) for 10 min at room temperature. The supernatant was collected from 
each well and diluted 1:10 with the 10% cetyl pyridinium chloride and read at OD550nm on a 
SpectraMAX Microplate Reader (Molecular Devices, USA). 
 
3.8 Statistical Analysis  
All statistical analyses were carried out using Prism5 (GraphPad Software Inc. California, 
USA). Unless otherwise stated, all data within figures represents Mean ±SEM. MTS assay 
results were assessed by a one-way analysis of variance (ANOVA) with a Tukey Post Hoc. 
OCR, ECAR and PPR, and alizarin red analysis was compared using a Students un-paired t-
test.  
 
RESULTS 
3.1 Acute exposure to PVI markedly reduces osteoblast proliferation. 
Acute 3 min exposure of primary human osteoblasts to PVI at the clinical concentration of 
0.35% significantly decreased cellular proliferation at 48, 120 and 168 h post-exposure 
(Figure 1A). Expressed as a percentage of normal osteoblast proliferation (PBS control), 
osteoblasts exposed to 0.35% PVI exhibited a 24 ± 3.7% decrease in proliferation after 24 h 
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(Figure 1B). This was a sustained response, which resulted in a 72% ± 2.3% decline in 
cellular proliferation at 1 week. The significant effect of PVI on cellular proliferation was 
also confirmed in the human osteoblast cell line (hFOB 1.19) (Figure 1C & 1D), with a 26 ± 
3% after 24 h, and a 42% ± 7% decline in proliferation relative to control after 6 days post-
exposure.  
 
3.2 Acute exposure of osteoblasts to dilute PVI ablates osteoblast basal metabolic 
function. 
Assessment of metabolic functional activity of osteoblasts (hFOB.1.19) 24 h post-exposure to 
0.35% PVI or PBS control showed a significant reduction in OCR (0.32±0.13 vs -0.05±0.12 
pmol/min/µg), ECAR (0.10±0.07 vs 0.01±0.02 mpH/min/µg) and PPR (87.64±18.78 vs 
3.33±7.24 pmol/min/µg) (Figure 2A-C) in osteoblasts that had been exposed to 0.35% PVI 
for 3 min.  
 
3.3 Acute exposure of human osteoblasts to PVI markedly reduces CIII-SDHB protein 
expression, a key component of oxidative phosphorylation. 
To identify if the effect of 0.35% PVI on osteoblast metabolic function was due to a 
deleterious effect on mitochondrial function we then assessed the protein expression of 
electron transport chain subunits (II, III and CV), involved in mitochondrial oxidative 
phosphorylation.  Human osteoblasts exposed to 0.35% PVI for 3 min exhibited a marked 
reduction in protein expression of succinate dehydrogenase B (CII-SDHB), and a moderate 
reduction in the protein expression of cytochrome b-c1 complex subunit 2 (CIII-UQCRC2), 
compared to PBS control exposed osteoblasts. The protein expression of CV-ATP5A 
remained unchanged (Figure 2D). 
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3.4 Acute stimulation with PVI reduces osteoblast mineralization 
We next determined whether the deleterious effects of 0.35% PVI on osteoblast proliferation 
and metabolic functional activity impacted on the ability of osteoblasts to form bone nodules 
and mineralise. At confluency, osteoblasts were stimulated with 0.35% PVI for 3 min, 
washed with PBS thoroughly and allowed to proliferate and differentiate for a further 2 
weeks in differentiation media. Alizarin red stained mineralisation was quantified and 
showed that osteoblasts exposed to 0.35% PVI exhibited significantly reduced bone nodule 
mineralisation (0.28±0.05), compared to control PBS exposed osteoblasts (0.37±0.06) (Figure 
3). 
 
Discussion 
PVI is advocated for wound irrigation following spinal surgery (8, 9), despite recent reports 
of its cytotoxicity in multiple cell types (10-13). Our in vitro study demonstrates that dilute 
PVI has fundamental deleterious effects on human osteoblast cells and their innate ability to 
mineralise. 
 
Utilising primary human osteoblasts, we have demonstrated that acute exposure of 
osteoblasts to PVI for only 3 min, followed by thorough washing, is sufficient to profoundly 
inhibit cellular proliferation. Dilute PVI was found to significantly inhibit proliferation within 
the first 24 h following the 3 min exposure to PVI. However, perhaps of greater concern, our 
data also reveals that the negative effects on proliferation are fully sustained over a time-
course of 7 days, resulting in a 72% inhibition of proliferation at this time point. This 
demonstrates that once exposed to dilute PVI the osteoblast cells do not recover their 
proliferative activity. Critically, we have also demonstrated that exposure to dilute PVI 
inhibits the innate functional ability of osteoblasts to form mineralised bone nodules.  
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Our data suggests that exposure to dilute PVI inhibits human osteoblast proliferation and 
mineralisation by preventing normal osteoblast metabolic function, since both basal oxygen 
consumption rate (a measure of aerobic mitochondrial respiration; (16)) and extracellular 
acidification rate and proton production rate (a measure of glycolytic metabolism; (16)) were 
ablated within 24 h post-exposure to 3 min of dilute PVI.    
 
With regard to previous studies which have reported the effect of PVI on the osteoblast, 
Kaysinger (1995) found that 5% Betadine (0.5% PVI) was toxic to chicken osteoblasts (15). 
It is of note that the first non-toxic concentration reported by Kaysinger was 5% Betadine 
(0.5% PVI). From their results it is therefore not possible to ascertain where between 0.05% 
and 0.5% the toxic effects of PVI are manifested (15). In the paper of Cheng et al. (8) the 
concentration of 0.5% PVI appears to have been interpreted as the lowest toxic concentration 
and hence guided their choice of 0.35% PVI for irrigation. We would argue that this was a 
fundamental misinterpretation of the report of Kaysinger et al. We have now confirmed that 
0.35% PVI is indeed toxic to human osteoblasts. 
 
Cabral et al (2007) assessed PVI exposure in human alveolar bone. They found 10% and 5% 
PVI resulted in immediate cell death. 1% PVI resulted in rounding up and cellular 
detachment (implied cell death), and that cellular proliferation was reduced at concentrations 
of 0.5% PVI and higher. Cabral also reported a significant reduction in Alkaline Phosphatase 
(AP) production at 0.05% and 0.2% PVI (14), indicative of reduced mineralisation activity. 
Our findings are in agreement with this, since we also found that PVI reduced osteoblast 
proliferation and have demonstrated a significant reduction in the production of mineralised 
bone (as measured by Alizarin red staining) with 0.35% PVI.  
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Infection rates in spinal surgery vary widely. For example, infection rate following anterior 
cervical surgery is low, at around 0.1%, but infection rates can be up to 19% in spinal 
deformity surgery (5, 17). Critically, the results of deep infection can be devastating and 
occasionally fatal in patient groups with multiple co-morbidities. Clearly therefore, efforts 
must be taken to reduce spinal infection. A very informative Best Practice Guideline in 2013 
made a number of recommendations for the “high risk” spinal surgical patients. These 
included pre-operative washing with chlorhexidine, nutritional assessment, broad spectrum 
antibiotics and topical vancomycin powder. It is noteworthy that PVI irrigation was not 
among the recommendations (18).  
 
In 2005 and 2006 two reports from the same centre described the utilization of 0.35% PVI 
lavage in spinal surgery (8, 9), and reported a clinically significant reduction in infection rates 
from 2.9% without PVI lavage, to 0.5% with PVI lavage. Clearly this is a commendable 
reduction in infection rates apparently attributable to the PVI lavage. However, the goal of 
many spinal surgeries is the establishment of solid bony fusion (union). Therefore, the 
potential negative effect of a given irrigate on bone union must be considered alongside any 
positive benefit on spinal infection rates.  
 
Measurement of union (and non-union) are difficult to comprehensively determine using 
Computed Tomography (CT) (Carreon et al. 2008). The only reliable method is surgical 
exploration. In lumbar fusion surgery non-union rates are reported to be 10-20%. In fusions 
of 4-levels or more, and in particular in adult degenerative scoliosis the rate of non-union can 
be as high as 20- 60% (9, 19-21). 
 
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Our study identifies a potential pathway for impaired bony union following PVI lavage in the 
clinical setting. The two reports from Cheng et al. (8) clearly state that on radiographic 
analysis there was no adverse effect on fusion rates. However, it is noteworthy that the 
patients in these studies were overwhelmingly 2-level or fewer low-back fusions. These 
particular patients have a fairly predictable union rate of around 80-90%. It is possible 
therefore that the deleterious effect of PVI on the human osteoblast may have a greater 
clinical impact on longer fusions with higher inherent risks of non-union. Additionally Chang 
et al. (9) used plain X-ray for evaluation of bony fusion. This is not a reliable method for 
assessing bony fusion, with only 68% accuracy in lumbar spine fusions (22).  
 
Outside the scope of this report, but of importance to the surgeon considering using PVI for 
irrigation of surgical wounds are descriptions of systemic complications following iodine 
lavage. These include: significant systemic iodine absorption, acute thyroid dysfunction, 
cardiovascular collapse, renal failure and death. Whilst these are not immediately relevant to 
bone healing, it does suggest that iodine lavage is not a universally benign phenomenon (23-
27). 
 
There are limitations to our study. It is not possible to replicate in vitro the entire biological 
system involved in bone healing. We cannot replicate or ascertain what the effect would be 
on the pluripotent stem cells that subsequently migrate to the site of bony healing after 
irrigation. We have only assessed the effect on one cell type (the osteoblast), we do not know 
what the effect of 0.35% PVI would be on other cell types involved in bone healing such as 
fibroblasts, osteoclasts and platelets. We also accept that although our primary osteoblasts 
were human, they were not isolated from spinal bone. It is therefore conceivable that 
osteoblasts within spinal bone could behave differently to osteoblasts from the appendicular 
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skeleton. It is reassuring however that our results are similar to those described by Kaysinger 
from chicken embryonic tibiae (15). 
 
In summary, we have demonstrated a clear deleterious effect of PVI to osteoblast 
proliferation and function and mineralisation. We suggest the advocated antimicrobial gains 
may be offset by the potential for impaired bone healing, particularly in long fusion 
procedures with higher non-union rates, where there is no clinical outcome data relating to 
PVI irrigation. 
 
Abbreviations 
 
PVI   Povidone-Iodine 
PBS   Phosphate buffered saline 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt 
CII-SDHB  Succinate Dehydrogenase B 
CIII-UQCRC2 ubiquinol-cytochrome c reductase core protein II 
CV-ATP5A  ATP synthase 
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Figure 1.  The effect of acute exposure to dilute PVI on the proliferation of primary human 
osteoblasts and a human osteoblast cell line.  A. Primary human osteoblasts stimulated with 
PBS and 0.35% PVI for 3 minutes prior to time dependent MTS assays.  ○ = PBS control; ● 
= 0.35% PVI stimulated (*p<0.05, ***p<0.001).  B. Percentage proliferation of primary 
osteoblasts when compared to PBS control stimulated osteoblasts (**p<0.01 between 24 and 
120 h, §p<0.001 between 24 and 168 h, †p<0.01 between 48 and 168 h). C. hFOB 1.19 cell 
proliferation as measured by MTS assay (*p<0.05, ***p<0.001).  D. Percentage proliferation 
of hFOB 1.19 osteoblasts when compared to PBS control stimulated osteoblasts (*p<0.05; 
n=3). 
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Figure 2. Metabolic activity of stable osteoblast culture following acute PVI stimulation. A. 
Oxygen consumption rate (OCR) of osteoblasts. B. Extracellular acidification rate of 
osteoblasts. C. Proton production rate of osteoblasts (Figure 2A-C n=4, *=p<0.05). D. 
Western blot of cells stimulated with 0.35% PVI or PBS control 24 h prior to lysis and 
assayed for mitochondrial protein expression (n=3). 
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Figure 3. Osteoblast mineralization following acute PVI stimulation. Alizarin red staining of 
osteoblasts treated with 0.35% PVI or PBS control was quantified at OD550nm using 10% cetyl 
pyridinium chloride. (n=8, **p<0.01).  
 
 
